Recherche

Afficher tous les résultats pour

Accueil

Concept

Recherche en oncologie

Science de la nature
Biologie
Biologie cellulaire
Cancer

À propos
Confidentialité
Mentions légales

Graph Chatbot

Publications associées (31)

Page 1 sur 2

Next-Generation Modeling of Cancer Using Organoids

Wouter Richard Karthaus, Jillian Rose Love

In the last decade, organoid technology has become a cornerstone in cancer research. Organoids are long-term primary cell cultures, usually of epithelial origin, grown in a three-dimensional (3D) protein matrix and a fully defined medium. Organoids can be ...

Cold Spring Harbor Lab Press, Publications Dept2024

NMR and MS reveal characteristic metabolome atlas and optimize esophageal squamous cell carcinoma early detection

Lijing Xin

Metabolic changes precede malignant histology. However, it remains unclear whether detectable characteristic metabolome exists in esophageal squamous cell carcinoma (ESCC) tissues and biofluids for early diagnosis. Here, we conduct NMR- and MS-based metabo ...

Nature Portfolio2024

Development of cysteine cathepsin inhibitors combined with cell type-specific delivery for the treatment of B-cell lymphoma and solid tumors

Aaron Simone Petruzzella

Cysteine cathepsins proteases are enzymes that play essential physiological roles, but their activity is also associated to different aspects of cancer progression and to the development of other diseases. Therefore, cysteine cathepsins are relevant and pr ...

EPFL2024

Cytokine-armed dendritic cell progenitors for antigen-agnostic cancer immunotherapy

Ali Ghasemi

Dendritic cells (DCs) are specialized myeloid cells with the ability to uptake, process, and present antigens to T lymphocytes. They also generate cytokine and chemokine gradients that regulate immune cell trafficking, activation, and function. Monocyte-de ...

EPFL2024

Tumor-educated Gr1+CD11b+cells drive breast cancer metastasis via OSM/IL-6/JAK-induced cancer cell plasticity

Nadine Fournier, Annamaria Kauzlaric, Manon Bulliard, Rachel Marcone

Cancer cell plasticity contributes to therapy resistance and metastasis, which represent the main causes of cancer-related death, including in breast cancer. The tumor microenvironment drives cancer cell plasticity and metastasis, and unraveling the underl ...

Amer Soc Clinical Investigation Inc2024

The conceptual foundations of innate immunity: Taking stock 30 years later

Bruno Lemaitre

While largely neglected over decades during which adaptive immunity captured most of the attention, innate immune mechanisms have now become central to our understanding of immunology. Innate immunity provides the first barrier to infection in vertebrates, ...

2024

Exploration and modulation of mechanical cues for enhanced cancer immunotherapy

Armand Kurum

The advent of immunotherapy, such as immune checkpoint blockade (ICB) and adoptive transfer of cytotoxic lymphocytes, has transformed the clinical care of cancer. However, a significant proportion of patients are resistant to immunotherapy or experience re ...

EPFL2024

Delivery of mRNA for cancer therapy: progress and prospects

Yi Wang

Synthetic messenger RNA (mRNA)-based therapeutics have emerged as promising candidates for the prevention and treatment of a wide range of diseases and disorders. mRNA possesses notable advantages, including exceptional safety, the capacity to replace vari ...

Elsevier Sci Ltd2023

Cancer hallmarks intersect with neuroscience in the tumor microenvironment

Douglas Hanahan

The mechanisms underlying the multistep process of tumorigenesis can be distilled into a logical framework involving the acquisition of functional capabilities, the so-called hallmarks of cancer, which are collectively envisaged to be necessary for maligna ...

CELL PRESS2023

Development of a novel Chimeric Antigen Receptor (CAR) for its use in Natural Killer (NK) cells for cancer treatment and beyond

Angela Madurga Alonso

The use of CAR technologies has revolutionized cancer treatment. Their unprecedented efficacy against B cell malignancies has opened the doors for a lot of excitement and research in the field. These synthetic receptors are composed of an antigen recogniti ...

EPFL2023

Tumor dormancy: EMT beyond invasion and metastasis

Cathrin Brisken, Patrik Aouad, Hazel Margaret Quinn

More than two-thirds of cancer-related deaths are attributable to metastases. In some tumor types metastasis can occur up to 20 years after diagnosis and successful treatment of the primary tumor, a phenomenon termed late recurrence. Metastases arise from ...

WILEY2023

Metabolic dependencies of metastasis-initiating cells in female breast cancer

Jörg Hülsken, Albert Santamaria Martinez, Candice Megan T Young, Pierre Vincent Dessen, Angela Madurga Alonso, Laurent Nam Ky Beziaud

Understanding the mechanisms that enable cancer cells to metastasize is essential in preventing cancer progression. Here we examine the metabolic adaptations of metastasis-initiating cells (MICs) in female breast cancer and how those shape their metastatic ...

Nature Portfolio2023

Direct In Vivo Activation of T Cells with Nanosized Immunofilaments Inhibits Tumor Growth and Metastasis

Bart Deplancke, Guido Van Mierlo, Jorieke Weiden

Adoptive T cell therapyhas successfully been implementedfor thetreatment of cancer. Nevertheless, ex vivo expansion of T cells byartificial antigen-presenting cells (aAPCs) remains cumbersome andcan compromise T cell functionality, thereby limiting their t ...

AMER CHEMICAL SOC2023

Medical and Personal Characteristics Can Predict the Risk of Lung Metastasis

Michele De Palma, Nahal Mansouri

Aims: Understanding the correlations between underlying medical and personal characteristics of a patient with cancer and the risk of lung metastasis may improve clinical management and outcomes. We used machine learning methodologies to predict the risk o ...

2023

A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response

Jaume Bonet Martinez

Immune checkpoint blockade (ICB) with antibodies has shown durable clinical responses in a wide range of cancer types, but the overall response rate is still limited. Other effective therapeutic modalities to increase the ICB response rates are urgently ne ...

TAYLOR & FRANCIS INC2023

Pan-cancer atlas of somatic core and linker histone mutations

Sebastian Martin Waszak

Recent genomic data points to a growing role for somatic mutations altering core histone and linker histone-encoding genes in cancer. However, the prevalence and the clinical and biological implications of histone gene mutations in malignant tumors remain ...

2023

Multiomic analysis of HER2-enriched and AR-positive breast carcinoma with apocrine differentiation and an oligometastatic course: a case report

Andrea Cavalli

Breast carcinoma is the most prevalent cancer among women globally. It has variable clinical courses depending on the stage and clinical-biological features. This case report describes a 56-year-old female with invasive breast cancer without estrogen or pr ...

FRONTIERS MEDIA SA2023

Nanotechnology enabled modulation of T cell immunity for cancer treatment

Xiaomeng Hu

Recent breakthroughs in cancer immunotherapy, exemplified by immune checkpoint blockade and CAR T cell therapy, have achieved remarkable clinical success. However, the majority of cancer patients fail to respond to immunotherapy or suffer from relapse. Nan ...

EPFL2023

Il-10 expressing cells for enhanced cancer immunotherapies

Li Tang, Yugang Guo, Yang Zhao

The present invention relates generally to the field of anti-cancer therapy, in particular to the use of adoptive T cell transfer therapy for treating cancer, in particular sold tumors. More specifically, the present invention relates to immune cells compr ...

2023

Balancing the Nanoscale Organization in Multivalent Materials for Functional Inhibition of the Programmed Death-1 Immune Checkpoint

Maartje Martina Cornelia Bastings, Kaltrina Paloja, Jorieke Weiden

Dendritic cells (DCs) regulate immune priming by expressing programmed death ligand 1 (PD-L1) and PD-L2, which interact with the inhibitory receptor PD-1 on activated T cells. PD-1 signaling regulates T cell effector functions and limits autoimmunity. Tumo ...

Amer Chemical Soc2023